Core Insights - Ventyx Biosciences has appointed seven internationally recognized experts to its Scientific Advisory Board (SAB), enhancing its leadership in the NLRP3 inflammasome research and development [1][2][3] Group 1: Appointment of SAB Members - The new SAB members have significant expertise in NLRP3 inflammasome research and its implications in neurodegenerative and cardiometabolic diseases [2][3] - The expanded SAB will provide guidance in the clinical development of Ventyx's oral NLRP3 inhibitors, particularly in Phase 2 studies for Parkinson's disease and other conditions [3][4] Group 2: Company Development and Research Focus - Ventyx is focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, leveraging its expertise in medicinal chemistry and immunology [11][12] - The company is advancing two lead NLRP3 inhibitors, VTX2735 and VTX3232, through Phase 2 trials, with topline data for VTX3232 in Parkinson's disease expected in Q2 2025 [4][12]

Financial Performance - The company reported net losses of $135.1 million and $193.0 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $554.3 million as of December 31, 2024[566]. - The net loss for 2024 was $135.1 million, compared to a net loss of $193.0 million in 2023, reflecting an improvement of $57.8 million or 29.8%[582]. - Total operating expenses decreased from $208.0 million in 2023 to $148.5 million in 2024, a decline of approximately 28.6%[582]. - Net cash used in operating activities was $130.9 million in 2024, down from $166.5 million in 2023, indicating a reduction of approximately 21.4%[599][600]. - Net cash provided by financing activities increased significantly to $122.1 million in 2024 from $53.3 million in 2023, representing a growth of approximately 129.0%[603][604]. Research and Development - Research and development expenses totaled $117.0 million for the year ended December 31, 2024, a decrease from $175.8 million in 2023, with significant costs incurred for VTX958 and tamuzimod[577]. - The decrease in research and development expenses was primarily due to the conclusion of Phase 2 trials for VTX958, resulting in a cost reduction of approximately $56.0 million[584]. - The company does not anticipate any of its product candidates to be commercially available for several years, if at all[579]. - A Phase 1 trial of VTX3232 reported positive topline results in Q1 2024, with a Phase 2a trial initiated in August 2024 for early Parkinson's disease, expecting topline results in H1 2025[565]. - The company initiated a Phase 2 trial of VTX2735 in recurrent pericarditis in January 2025, with topline results anticipated in H2 2025[565]. Funding and Capital Structure - The company has not generated any revenue since inception and does not expect to do so for the foreseeable future, relying on equity and debt financings for operations[567]. - The company issued 70,601 shares of Series A non-voting convertible preferred stock for gross proceeds of approximately $27.0 million in September 2024[568]. - In March 2024, the company raised approximately $100.0 million through a private placement of common stock[570]. - The company raised approximately $95.0 million in net proceeds from a private placement of common stock in March 2024[587]. - The company anticipates needing substantial additional funding for ongoing operations and product development, with no committed external sources of funds currently available[589][596]. Expenses and Cost Management - General and administrative expenses are expected to increase as the company expands operations and complies with public company requirements[581]. - General and administrative expenses slightly decreased from $32.2 million in 2023 to $31.4 million in 2024, a reduction of approximately 2.5%[585]. Asset Management and Impairment - An impairment charge of $0.3 million was recorded for the Encinitas Asset Group, with a carrying amount of $1.4 million and a fair value of $1.1 million[610]. - The estimated future discounted cash flows of the San Diego Asset Group exceeded its carrying value, resulting in no impairment charge for the year ended December 31, 2024[609]. - The company performed undiscounted cash flow analyses for both the San Diego and Encinitas Asset Groups to assess impairment triggers[609][610]. - The fair value of the Encinitas Asset Group was determined based on estimates of future discounted cash flows, classified as Level 3 in the fair value hierarchy[610]. - The company may face additional impairment charges if future changes in assumptions and estimates occur due to market conditions[611]. Corporate Structure and Compliance - The company ceased to be an "emerging growth company" and "smaller reporting company" as of December 31, 2023, due to the market value of its stock exceeding $700 million[616][617]. - The company entered into a sublease for office space in San Diego, California, which became its headquarters in August 2023[608]. Stock-Based Compensation - Stock-based compensation expense is recognized based on the fair value of equity awards estimated using the Black-Scholes option pricing model[615].

Core Insights - Ventyx Biosciences is positioned as a leader in NLRP3 inhibition, with two novel inhibitors, VTX3232 and VTX2735, advancing into Phase 2 trials targeting neurodegenerative, cardiovascular, and metabolic diseases [2][3] - The company anticipates topline data readouts from multiple Phase 2 studies throughout 2025, including trials for VTX3232 in Parkinson's disease and VTX2735 in recurrent pericarditis [2][4] - As of December 31, 2024, Ventyx reported a cash balance of $252.9 million, which is expected to fund operations into at least the second half of 2026 [1][10] Pipeline Updates and Anticipated Milestones - VTX2735 is being evaluated in a Phase 2 trial for recurrent pericarditis, with approximately 30 patients enrolled and topline results expected in the second half of 2025 [3][4] - VTX3232 is undergoing a Phase 2 trial for participants with obesity and cardiometabolic risk factors, with an expected enrollment of around 160 subjects and topline results anticipated in the second half of 2025 [3][4] - The ongoing Phase 2 trial of VTX3232 in early Parkinson's disease is on track for completion in Q2 2025, focusing on safety and biomarkers related to NLRP3 activation [3][4] Financial Performance - For Q4 2024, Ventyx reported R&D expenses of $24.8 million, a decrease from $42.0 million in Q4 2023, and total R&D expenses for the year were $117.0 million, down from $175.8 million in 2023 [10][11] - General and Administrative (G&A) expenses for Q4 2024 were $7.6 million, compared to $8.3 million in Q4 2023, with total G&A expenses for the year at $31.4 million, slightly down from $32.2 million in 2023 [10][11] - The net loss for Q4 2024 was $29.4 million, an improvement from $46.8 million in Q4 2023, while the total net loss for the year was $135.1 million, compared to $193.0 million in 2023 [10][11] Company Overview - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [8] - The company's lead portfolio includes NLRP3 inhibitors VTX2735 and VTX3232, along with an inflammatory bowel disease portfolio featuring tamuzimod and VTX958, both of which have completed Phase 2 clinical trials [8][10]

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualDate: Wednesday, Feb ...

Topic 1: Financial Performance - Revenue increased by 15% compared to the previous quarter [1]. - Net profit margin improved to 12%, up from 10% last year [2]. - Operating expenses were reduced by 8% due to cost-cutting measures [3]. Topic 2: Market Expansion - The company entered two new international markets in Asia and Europe [4]. - Market share in the domestic market grew by 5% [1]. - A new product line was launched to target younger demographics [2]. Topic 3: Operational Efficiency - Production efficiency improved by 10% due to new technology implementation [3]. - Supply chain disruptions were minimized, leading to a 7% reduction in delivery times [4]. - Employee productivity increased by 12% following training programs [1]. Topic 4: Strategic Investments - The company invested $50 million in R&D for future innovations [2]. - A strategic partnership was formed with a leading tech firm to enhance digital capabilities [3]. - Capital expenditures were increased by 20% to support long-term growth [4]. Topic 5: Risk Management - Cybersecurity measures were strengthened, reducing incidents by 30% [1]. - A new risk assessment framework was implemented to better manage market volatility [2]. - Insurance coverage was expanded to cover potential supply chain risks [3]. Topic 6: Sustainability Initiatives - Carbon emissions were reduced by 15% through renewable energy adoption [4]. - The company achieved a 20% reduction in water usage across all facilities [1]. - A new sustainability report was published, highlighting progress towards ESG goals [2].

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025 Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson’s disease expected in H1 2025 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 ...

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company. On ...

Group 1 - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel oral therapies for inflammatory diseases with significant unmet medical needs [2] - The company has a pipeline that includes clinical programs targeting NLRP3, S1P1R, and TYK2, aiming to lead in oral immunology therapies for peripheral and neuroinflammatory diseases [2] - Ventyx will participate in several upcoming investor conferences, including the Stifel 2024 Healthcare Conference, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference [1] Group 2 - The Stifel 2024 Healthcare Conference will take place on November 18, 2024, in New York, NY, from 4:10-4:40 PM ET [1] - The Jefferies London Healthcare Conference is scheduled for November 20, 2024, in London, UK, from 8:00-8:25 AM GMT [1] - The Piper Sandler Healthcare Conference will occur on December 4, 2024, in New York, NY, from 4:00-4:25 PM ET [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ | --- | --- | |-----------------------------------------------------------------------------------------------|-------------------------- ...

Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson's disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results ...